Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive impairment: Results of a pilot randomized clinical trial

Journal of the American Geriatrics Society

Volumn 61, Issue 2, 2013, Pages 194-201

  Hajjar, Ihab ^a   Hart, Meaghan ^b   Chen, Yu Ling ^c   MacK, Wendy ^c   Novak, Vera ^d   Chui, Helena C ^a   Lipsitz, Lewis ^b,d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Hebrew Seniorlife's Res Institute   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

angiotensin receptor blocker; cerebrovascular circulation; executive function hemodynamics; hypertension

Indexed keywords

CANDESARTAN; CARBON DIOXIDE; HYDROCHLOROTHIAZIDE; LISINOPRIL; METOPROLOL; NIFEDIPINE;

ADD ON THERAPY; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD FLOW VELOCITY; BRAIN BLOOD FLOW; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOPPLER ECHOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; EXECUTIVE FUNCTION; FATIGUE; FEMALE; HEMODYNAMICS; HUMAN; HYPERCAPNIA; HYPERTENSION; HYPOCAPNIA; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; REST; SITTING; STANDING; SYSTOLIC BLOOD PRESSURE; WEAKNESS;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BLOOD PRESSURE; CEREBROVASCULAR CIRCULATION; COGNITION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; PILOT PROJECTS; REGIONAL BLOOD FLOW; TETRAZOLES; TREATMENT OUTCOME;

EID: 84873986055     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/jgs.12100     Document Type: Article

References (40)

1. Vicario A, Martinez CD, Baretto D, et al. Hypertension and cognitive decline: Impact on executive function. J Clin Hypertens (Greenwich) 2005; 7: 598-604.
2. Grigsby J, Kaye K, Shetterly SM, et al. Prevalence of disorders of executive cognitive functioning among the elderly: Findings from the San Luis Valley Health and Aging Study. Neuroepidemiology 2002; 21: 213-220.
3. Royall DR, Espino DV, Polk MJ, et al. Prevalence and patterns of executive impairment in community dwelling Mexican Americans: Results from the Hispanic EPESE Study. Int J Geriatr Psychiatry 2004; 19: 926-934.
4. Rockwood K, Wentzel C, Hachinski V, et al. Prevalence and outcomes of vascular cognitive impairment. Vascular Cognitive Impairment Investigators of the Canadian Study of Health and Aging. Neurology 2000; 54: 447-451.
5. Hajjar I, Quach L, Yang F, et al. Hypertension, white matter hyperintensities, and concurrent impairments in mobility, cognition, and mood: The Cardiovascular Health Study. Circulation 2011; 123: 858-865.
6. Zazulia AR,. Regulation of cerebral blood flow in untreated mild-to-moderate hypertension. Am J Hypertens 2009; 22: 344.
7. Ficzere A, Valikovics A, Fulesdi B, et al. Cerebrovascular reactivity in hypertensive patients: A transcranial Doppler study. J Clin Ultrasound 1997; 25: 383-389.
8. Poels MM, Ikram MA, Vernooij MW, et al. Total cerebral blood flow in relation to cognitive function: The Rotterdam Scan Study. J Cereb Blood Flow Metab 2008; 28: 1652-1655.
9. Kazama K, Anrather J, Zhou P, et al. Angiotensin II impairs neurovascular coupling in neocortex through NADPH oxidase-derived radicals. Circ Res 2004; 95: 1019-1026.
10. Saavedra JM, Nishimura Y,. Angiotensin and cerebral blood flow. Cell Mol Neurobiol 1999; 19: 553-573.
11. Hajjar I, Sorond F, Hsu YH, et al. Renin angiotensin system gene polymorphisms and cerebral blood flow regulation: The MOBILIZE Boston study. Stroke 2010; 41: 635-640.
12. Horiuchi M, Mogi M, Iwai M,. The angiotensin II type 2 receptor in the brain. J Renin Angiotensin Aldosterone Syst 2010; 11: 1-6.
13. Hajjar I, Hart M, Milberg W, et al. The rationale and design of the Antihypertensives and Vascular, Endothelial, and Cognitive Function (AVEC) trial in elderly hypertensives with early cognitive impairment: Role of the renin angiotensin system inhibition. BMC Geriatr 2009; 9: 48.
14. Royall DR, Cordes JA, Polk M,. CLOX: An executive clock drawing task. J Neurol Neurosurg Psychiatry 1998; 64: 588-594.
15. Crum RM, Anthony JC, Bassett SS, et al. Population-based norms for the Mini-Mental State Examination by age and educational level. JAMA 1993; 269: 2386-2391.
16. Washburn RA, Ficker JL,. Physical Activity Scale for the Elderly (PASE): The relationship with activity measured by a portable accelerometer. J Sports Med Phys Fitness 1999; 39: 336-340.
17. Lawton MP, Brody EM,. Assessment of older people: Self-maintaining and instrumental activities of daily living. Gerontologist 1969; 9: 179-186.
18. Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: Blood pressure measurement in humans: A statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension 2005; 45: 142-161.
19. Sorond FA, Serrador JM, Jones RN, et al. The sit-to-stand technique for the measurement of dynamic cerebral autoregulation. Ultrasound Med Biol 2009; 35: 21-29.
20. Wallenstein S, Wittes J,. The power of the Mantel-Haenszel test for grouped failure time data. Biometrics 1993; 49: 1077-1087.
21. Iwai M, Inaba S, Tomono Y, et al. Attenuation of focal brain ischemia by telmisartan, an angiotensin II type 1 receptor blocker, in atherosclerotic apolipoprotein E-deficient mice. Hypertens Res 2008; 31: 161-168.
22. Kobayashi T, Kawamata T, Shibata N, et al. Angiotensin II type 1 receptor blocker telmisartan reduces cerebral infarct volume and peri-infarct cytosolic phospholipase A(2) level in experimental stroke. J Neurotrauma 2009; 26: 2355-2364.
23. Omura-Matsuoka E, Yagita Y, Sasaki T, et al. Postischemic administration of angiotensin II type 1 receptor blocker reduces cerebral infarction size in hypertensive rats. Hypertens Res 2009; 32: 548-553.
24. Oyama N, Yagita Y, Sasaki T, et al. An angiotensin II type 1 receptor blocker can preserve endothelial function and attenuate brain ischemic damage in spontaneously hypertensive rats. J Neurosci Res 2010; 88: 2889-2898.
25. Takeda S, Sato N, Takeuchi D, et al. Angiotensin receptor blocker prevented beta-amyloid-induced cognitive impairment associated with recovery of neurovascular coupling. Hypertension 2009; 54: 1345-1352.
26. Kimura Y, Kitagawa K, Oku N, et al. Blood pressure lowering with valsartan is associated with maintenance of cerebral blood flow and cerebral perfusion reserve in hypertensive patients with cerebral small vessel disease. J Stroke Cerebrovasc Dis 2010; 19: 85-91.
27. Matsumoto S, Shimodozono M, Miyata R, et al. Effect of the angiotensin II type 1 receptor antagonist olmesartan on cerebral hemodynamics and rehabilitation outcomes in hypertensive post-stroke patients. Brain Inj 2009; 23: 1065-1072.
28. Gelosa P, Pignieri A, Fandriks L, et al. Stimulation of AT2 receptor exerts beneficial effects in stroke-prone rats: Focus on renal damage. J Hypertens 2009; 27: 2444-2451.
29. Kaschina E, Unger T,. Angiotensin AT1/AT2 receptors: Regulation, signalling and function. Blood Press 2003; 12: 70-88.
30. Li J, Culman J, Hortnagl H, et al. Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury. FASEB J 2005; 19: 617-619.
31. Hajjar I, Hart M, Chen YL, et al. Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: A double-blind randomized clinical trial. Arch Intern Med 2012; 172: 442-444.
32. Cohen RA,. Hypertension and cerebral blood flow: Implications for the development of vascular cognitive impairment in the elderly. Stroke 2007; 38: 1715-1717.
33. Girouard H, Iadecola C,. Neurovascular coupling in the normal brain and in hypertension, stroke, and Alzheimer disease. J Appl Physiol 2006; 100: 328-335.
34. Chao LL, Pa J, Duarte A, et al. Patterns of cerebral hypoperfusion in amnestic and dysexecutive MCI. Alzheimer Dis Assoc Disord 2009; 23: 245-252.
35. Silvestrini M, Pasqualetti P, Baruffaldi R, et al. Cerebrovascular reactivity and cognitive decline in patients with Alzheimer disease. Stroke 2006; 37: 1010-1015.
36. Vicenzini E, Ricciardi MC, Altieri M, et al. Cerebrovascular reactivity in degenerative and vascular dementia: A transcranial Doppler study. Eur Neurol 2007; 58: 84-89.
37. Rompe F, Artuc M, Hallberg A, et al. Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaB. Hypertension 2010; 55: 924-931.
38. Wilms H, Rosenstiel P, Unger T, et al. Neuroprotection with angiotensin receptor antagonists: A review of the evidence and potential mechanisms. Am J Cardiovasc Drugs 2005; 5: 245-253.
39. Ghiadoni L, Virdis A, Magagna A, et al. Effect of the angiotensin II type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension. Hypertension 2000; 35: 501-506.
40. Kontos HA,. Validity of cerebral arterial blood flow calculations from velocity measurements. Stroke 1989; 20: 1-3.